Back

REDUCE-IT: outcomes by baseline statin type

28 August 2020 (08:00 - 18:00)
Organised by:
Congress Presentation Part of: Pharmacology and Pharmacotherapy ePosters Lipid-Lowering Agents ESC Premium Access ESC Congress 2020

About the speaker

Photo
Professor Deepak Bhatt

Icahn School of Medicine at Mount Sinai, New York City (United States of America)

56 More presentations in this session

Presentation thumbnail
Tafolecimab, a novel potential long-acting PCSK9 monoclonal antibody: efficacy and safety in healthy and hypercholesterolemia subjects
Professor Y. Huo (Beijing, CN)
Abstract Slides
Presentation thumbnail
Vericiguat clinical pharmacology programme: biopharmaceutical properties and potential intrinsic and extrinsic factor effects
Doctor C. Becker (Wuppertal, DE)
Abstract Slides
Presentation thumbnail
Physiologically-based pharmacokinetic (PBPK) exploration of extrinsic factors influencing vericiguat pharmacokinetics
Doctor S. Frechen (Leverkusen, DE)
Abstract Slides
Presentation thumbnail
Long-term safety and efficacy of bempedoic acid in patients at high risk of atherosclerotic cardiovascular disease: results from the CLEAR Harmony open-label extension study
Doctor C. Ballantyne (Houston, US)
Abstract Slides
Presentation thumbnail
The effect of elevated triglycerides and purified eicosapentaenoic acid ethyl ester (EPA) for cardiovascular risk reduction in the UK Biobank population
Doctor D. Radenkovic (Greater London, GB)
Abstract Slides

Access the full session

Session thumbnail
Pharmacology and Pharmacotherapy ePosters

The Event

Event poster

ESC Congress 2020

28 August 2020 08:00 CET
You may be interested in
thumbnail
Congress Presentation
Icosapent ethyl reduces cardiovascular risk across apolipoprotein b and fasting triglyceride rich lipoprotein levels
30 August 2025
thumbnail
Congress Presentation
Inter-individual variability in LDL-C reductions with inclisiran - Data from ORION-10 and ORION-11
1 September 2020
thumbnail
Congress Presentation
The association between dyslipidaemia treatment and the risk of clinical events in edoxaban-treated patients with atrial fibrillation: insights from the 2-year follow-up of ETNA-AF-Europe
28 August 2022
thumbnail
Congress Presentation
Cost-effectiveness of icosapent ethyl for primary and secondary cardiovascular prevention in the UK
27 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources